These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31911033)

  • 1. Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals.
    Burkhard J; Ciurea A; Gabay C; Hasler P; Müller R; Niedrig M; Fehr J; Villiger P; Visser LG; de Visser AW; Walker UA; Hatz C; Bühler S
    Vaccine; 2020 Apr; 38(19):3610-3617. PubMed ID: 31911033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of immunity in recipients of two doses of 17DD yellow fever vaccine.
    Collaborative group for studies on yellow fever vaccines
    Vaccine; 2019 Aug; 37(35):5129-5135. PubMed ID: 31171393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
    Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
    Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.
    Kareko BW; Booty BL; Nix CD; Lyski ZL; Slifka MK; Amanna IJ; Messer WB
    J Infect Dis; 2020 Jun; 221(12):2018-2025. PubMed ID: 31545367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa.
    Jia Q; Jia C; Liu Y; Yang Y; Qi J; Tong L; Chen H; Zhang M; Che J; Li B; Li Z
    Antiviral Res; 2019 Feb; 162():1-4. PubMed ID: 30529359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
    Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
    J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
    Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients.
    Avelino-Silva VI; Miyaji KT; Hunt PW; Huang Y; Simoes M; Lima SB; Freire MS; Caiaffa-Filho HH; Hong MA; Costa DA; Dias JZ; Cerqueira NB; Nishiya AS; Sabino EC; Sartori AM; Kallas EG
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005219. PubMed ID: 27941965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial.
    Roukens AHE; van Halem K; de Visser AW; Visser LG
    Ann Intern Med; 2018 Dec; 169(11):761-765. PubMed ID: 30476963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
    Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
    Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
    J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
    da Costa-Rocha IA; Machado KLLL; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; de Lima SMB; Miranda EH; Trindade GF; Casagrande TZ; Miyamoto ST; Deotti SC; Barbosa RVR; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Valim V; Martins-Filho OA
    Sci Rep; 2021 May; 11(1):10431. PubMed ID: 34001945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.
    Colin de Verdiere N; Durier C; Samri A; Meiffredy V; Launay O; Matheron S; Mercier-Delarue S; Even S; Aboulker JP; Molina JM; Autran B; Simon F;
    AIDS; 2018 Oct; 32(16):2291-2299. PubMed ID: 30096071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
    Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort study.
    Doshi RH; Mukadi PK; Casey RM; Kizito GM; Gao H; Nguete U B; Laven J; Sabi L; Kaba DK; Muyembe-Tamfum JJ; Hyde TB; Ahuka-Mundeke S; Staples JE
    Lancet Infect Dis; 2024 Jun; 24(6):611-618. PubMed ID: 38335976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
    Ma J; Yakass MB; Jansen S; Malengier-Devlies B; Van Looveren D; Sanchez-Felipe L; Vercruysse T; Weynand B; Javarappa MPA; Quaye O; Matthys P; Roskams T; Neyts J; Thibaut HJ; Dallmeier K
    EBioMedicine; 2022 Sep; 83():104240. PubMed ID: 36041265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
    Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule.
    Veit O; Domingo C; Niedrig M; Staehelin C; Sonderegger B; Héquet D; Stoeckle M; Calmy A; Schiffer V; Bernasconi E; Flury D; Hatz C; Zwahlen M; Furrer H;
    Clin Infect Dis; 2018 Mar; 66(7):1099-1108. PubMed ID: 29140432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.